The dramatic growth of a key federal drug discount program has fueled debate about whether it is helping low-income patients as intended or primarily benefiting health care providers.

Tax-exempt hospitals participating in the 340B Drug Pricing Program provided nearly $100 billion in total community benefits in 2022. According to ...

Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy (R-Louisiana) recently released the results of an investigation into the 340B Drug Pricing Program. Here are four key ...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...

Ryan Long, the co-author of a recent USC Schaeffer Center white paper on the 340B Drug Pricing Program, argues that meaningful reform requires shifting to a direct subsidy model based on need.

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

The 340B Drug Pricing Program was created to benefit low-income and uninsured Americans. Over time, it has morphed into a federal subsidy for hospitals in affluent areas at the expense ...

The American Hospital Association and America's Essential Hospitals have joined five other 340B stakeholders in a lawsuit against the Department of Health and Human Services over its delay in ...

Having served in both state and federal government, I know it is far too rare for elected officials to stand up to special interests with appropriate skepticism. That is why Michigan's House Speaker ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...